BIO tells SEC: do away with quar­ter­ly re­ports for small biotechs

Pres­i­dent Don­ald Trump last Au­gust asked the SEC to look in­to the fea­si­bil­i­ty of abol­ish­ing the quar­ter­ly re­port­ing re­quire­ment in fa­vor of a six-month sys­tem. The reg­u­la­tor re­cent­ly posed this ques­tion to BIO — the largest trade or­ga­ni­za­tion rep­re­sent­ing bio­phar­ma — whether a less fre­quent re­port­ing regime would work for its mem­bers, some of whom spend a for­tune over a decade be­fore their prod­ucts hit the mar­ket… if they ever do.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER